drugset / Trial / NCT05371899
Mass Balance Study of [14C]Chiauranib
NaSingle-groupOpen-labelTreatment
Summary
Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Timeline
- Start
- 2022-07-20
- Primary completion
- 2024-03-18
- Completion
- 2024-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBCASERTIB | Small molecule | 50 mg | Oral |